Merck (MRK) said Tuesday that Health Canada has granted approval for Keytruda as a treatment for adult patients with resectable Stage II, IIIA, or IIIB non-small cell lung carcinoma.
The approval is for Keytruda to be administered in combination with platinum-containing chemotherapy as neoadjuvant treatment and as a monotherapy for adjuvant treatment after surgery, Merck said.
The company said the approval was based on the results of a phase 3 trial, where Keytruda demonstrated "statistically significant" results for the primary endpoints of event-free survival and overall survival.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。